TNL Mediagene Inc. (TNMG)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TNL Mediagene (NASDAQ:TNMG) Sees Significant Decrease in Short Interest
TNL Mediagene (NASDAQ: TNMG - Get Free Report) saw a large decrease in short interest in February. As of February 27th, there was short interest totaling 119,590 shares, a decrease of 16.2% from the February 12th total of 142,701 shares. Currently, 7.9% of the company's stock are sold short. Based on an average trading volume of
TNL Mediagene Inc. (TNMG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has TNL Mediagene Inc. ever had a stock split?
TNL Mediagene Inc. Profile
| Media Industry | Communication Services Sector | Motoko Imada CEO | NASDAQ (CM) Exchange | G8924F105 CUSIP |
| JP Country | 500 Employees | - Last Dividend | 23 Dec 2025 Last Split | - IPO Date |
Overview
AdAlta Limited is a pioneering clinical stage biotechnology entity focused on the discovery and development of innovative protein therapeutics, headquartered in Bundoora, Australia. Grounded on its proprietary i-body platform, AdAlta stands at the forefront of addressing significant unmet medical needs in fibrotic diseases and various cancers. Since its inception in 2006, AdAlta has committed itself to advancing medical science and improving patient outcomes through leveraging the unique capabilities of its i-body technology. The company’s strategic collaborations with notable entities such as GE Healthcare and Carina Biotech underscore its dedication to expanding the potential applications of its therapeutic solutions, highlighting a commitment not only to scientific excellence but also to fostering partnerships that enhance the development and delivery of cutting-edge healthcare solutions.
Products and Services
AD-214: A flagship antibody therapeutic developed by AdAlta, AD-214 is currently progressing through a Phase I clinical trial. Engineered to target and treat fibrotic diseases, this innovative therapeutic offers hope for conditions such as idiopathic pulmonary fibrosis and interstitial lung disease, as well as kidney, eye, and various other fibrotic conditions. By focusing on these areas, AD-214 represents a significant step forward in tackling diseases with considerable unmet treatment needs.
Collaboration with GE Healthcare: AdAlta and GE Healthcare have joined forces to pioneer the development of i-body enabled granzyme B PET imaging agents. This partnership aims to utilize the advanced capabilities of i-bodies for use in immuno-oncology, potentially revolutionizing the way cancers are diagnosed and monitored, paving the way for more effective and personalized treatment options. It is a testament to AdAlta’s ability to leverage its platform technology in collaboration with industry leaders to contribute to significant advancements in cancer care.
Collaboration with Carina Biotech: The partnership between AdAlta and Carina Biotech focuses on the development of CAR-T cell products targeting various solid tumor antigens. This collaborative effort seeks to combine the strengths of AdAlta’s i-body technology with Carina Biotech’s expertise in CAR-T cell therapies, aiming to develop groundbreaking treatments for solid tumors. Such endeavors not only showcase AdAlta’s versatile application of its i-body platform but also underscore its role in pioneering the future of oncological treatments.
